Piper initiates Pharmacyclics ( PCYC ) at Overweight. Price target is $160. Piper upgrades Isis Pharmaceuticals ( ISIS ) to Neutral from Underweight. Piper starts Alexion ( ALXN ) at Overweight. Price target is $172. Post your comment!
Alexion should be able to leverage its existing infrastructure for the development and marketing of the drug. Alexion Pharmaceuticals specializes in the development and marketing of drugs for life-threatening medical conditions. The firm
Alexion Pharmaceuticals ( ALXN ) announces the presentation of data from four clinical trials of Soliris in aHUS. Data from two multinational studies show Soliris
By Joseph P. Porter : In 5 Biotechnology Bargains with Attractive Fundamentals I discussed the five least expensive biotechs that were chosen by my PIC criteria. As I mentioned in that article, the set of filters used on FINVIZ.com 's screener returned 15 companies, all of which exhibited what ...
By Smith On Stocks : Review of Amazing and Volatile Stock Price Performance From the closing price on December 30, 2011 through October 1, 2013, Celldex's ( CLDX ) stock price increased 15 fold from $2.60 to $37.83; its shares have recently backed off to about $26.00. The number of shares ...
Outperformed Google ( GOOG ): Priceline ( PCLN ), Monster Beverage ( MNST ), Apple ( AAPL ), Regeneron ( REGN ), Alexion ( ALXN ), Netflix ( NFLX ), Intuitive Surgical ( ISRG ), Salesforce.com ( CRM ), Cabot Oil & Gas ( COG ). Other stocks mentioned
(Reuters) - Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last...
Alexion ALXN reported second-quarter results that put it on track to meet our expectations for the full year, and we're maintaining our
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday July 1. Noodles & Company ( NDLS ). Other stock mentioned: Chipotle Mexican Grill ( CMG ) Noodles & Company ( NDLS ) was a red hot IPO that might go higher on a new food trend. It
Alexion Pharmaceuticals ' ALXN first-quarter results saw another period of eye-popping growth for rare-disease drug Soliris. The firm's updated guidance